Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | RXRA | P19793 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MPC2 | O95563 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2944707 | 0.99 | PPARG (0.66) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL8792213 | 0.89 | PPARG (0.52) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL7881745 | 0.88 | PPARG (0.48) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL5805537 | 0.87 | PPARG (0.53) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL7828079 | 0.86 | PPARG (0.52) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL1220739 | 0.86 | PPARG (0.48) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL28002443 | 0.85 | PPARG (0.60) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL1220487 | 0.85 | PPARG (0.47) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL20579732 | 0.85 | PPARG (0.69) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL20579578 | 0.85 | PPARG (0.69) | PPARGCYP3A4RXRAHPGDMPC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034518-A1 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-10 | — | — | US | claimed |
| US-7842706-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | claimed |
| EP-2253325-A1 | AGENT FOR ENHANCING CORNEAL EPITHELIAL BARRIER FUNCTION | Santen Pharmaceutical Co., Ltd (JP) | 2010-11-24 | — | — | EP | claimed |
| US-20090246232-A1 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2009-10-01 | — | — | US | claimed |
| EP-0974348-B1 | VISCERAL FAT LOWERING AGENT | NIPPON CHEMIPHAR CO (JP) | 2008-07-02 | — | — | EP | claimed |
| EP-1694646-B1 | PROCESS FOR THE SYNTHESIS OF PIOGLITAZONE HYDROGEN CHLORIDE | RICHTER GEDEON VEGYESZET (HU) | 2007-04-25 | — | — | EP | claimed |
| US-20070054943-A1 | Therapeutic agent for keratoconjunctival disorder | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | claimed |
| EP-1757603-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVA DISORDER | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | claimed |
| EP-1647289-A1 | Peroxisome proliferator-activated receptor gamma ligand eluting medical device | Medtronic Vascular, Inc. (US) | 2006-04-19 | — | — | EP | claimed |
| EP-0914158-B2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II ANTAGONISTIC ACTIVITY AND A COMPOUND WHICH INCREASES THE INSULIN-SENSITIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-01-25 | — | — | EP | claimed |
| EP-0893995-A1 | ANTICACHECTIC COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 1999-02-03 | — | — | EP | claimed |
| WO-1998055121-A1 | USE OF THIAZOLIDINEDIONE DERIVATIVES IN THE TREATMENT OF POLYCYSTIC OVARY SYNDROME AND GESTATIONAL DIABETES | WARNER-LAMBERT COMPANY (US) | 1998-12-10 | — | — | WO | claimed |
| WO-1997037688-A2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II AND ANTAGONISTIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-16 | — | — | WO | claimed |
| WO-1997037656-A1 | ANTICACHECTIC COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-16 | — | — | WO | claimed |
| EP-0508740-B1 | Thiazolidinedione derivatives, their production and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-10-01 | — | — | EP | claimed |
| US-5183823-A | PYRIDINE N-OXIDE COMPOUNDS WHICH ARE USEFUL AS HYPOGLYCEMIC AND HYPOLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-02 | — | — | US | claimed |
| EP-0508740-A1 | Thiazolidinedione derivatives, their production and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-14 | — | — | EP | claimed |
| EP-0193256-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1989-04-05 | — | — | EP | claimed |
| US-4687777-A | pioglitazone and salts | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-08-18 | — | — | US | claimed |
| EP-0193256-A1 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-09-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054943-A1 | Therapeutic agent for keratoconjunctival disorder | TSLP, KRT18, TLR5 | PPARG 345/4885CYP3A4 3838/4885RXRA 1532/4885 |
| US-20110034518-A1 | Pharmaceutical composition | GPR119, IAPP, INSR | PPARG 19/4885CYP3A4 389/4885RXRA 1384/4885 |
| US-20090246232-A1 | Pharmaceutical composition | GPR119, IAPP, INSR | PPARG 19/4885CYP3A4 389/4885RXRA 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.